Update on CVD 103-HgR single-dose, live oral cholera vaccine

References

• Gabutti G, Rossanese A, Tomasi A, et al. Cholera, the current status of cholera vaccines and recommendations for travellers. Vaccines (Basel). 2020Oct14;8(4). PubMed PMID: 33066373; eng. doi:https://doi.org/10.3390/vaccines8040606
   Google Scholar
• Legros D. Global cholera epidemiology: opportunities to reduce the burden of cholera by 2030. J Infect Dis. 2018Oct15;218(suppl_3):S137–s140. PubMed PMID: 30184102; PubMed Central PMCID: PMCPMC6207143; eng.
   PubMedGoogle Scholar
• Cholera vaccines: WHO position paper – August 2017. Wkly Epidemiol Rec. 2017Aug25;92(34):477–498. PubMed PMID: 28845659; eng.
   PubMedGoogle Scholar
• WHO. Cholera: key facts 2019 [ cited 2020 Accessed24 November 2021 24 November]. cited: https://www.who.int/news-room/fact-sheets/detail/cholera
   Google Scholar
• Reidl J, Klose KE. Vibrio cholerae and cholera: out of the water and into the host. FEMS Microbiol Rev. 2002Jun;26(2):125–139. PubMed PMID: 12069878; eng.
   PubMed Web of Science ®Google Scholar
• Mutreja A, Dougan G. Molecular epidemiology and intercontinental spread of cholera. Vaccine. 2020Feb29;38(Suppl 1):A46–a51. PubMed PMID: 31345641; eng.
   PubMedGoogle Scholar
• Weill FX, Domman D, Njamkepo E, et al. Genomic history of the seventh pandemic of cholera in Africa. Science. 2017Nov10;358(6364):785–789. PubMed PMID: 29123067; eng.
   PubMed Web of Science ®Google Scholar
• Nair GB, Takeda Y. Cholera outbreaks. Preface. Curr Top Microbiol Immunol. 2014;379:v–vii. PubMed PMID: 25299007; eng.
   PubMed Web of Science ®Google Scholar
• Wong KK, Burdette E, and Mahon BE, et al. Recommendations of the advisory committee on immunization practices for use of cholera vaccine. MMWR Morb Mortal Wkly Rep. 2017May12;66(18):482–485. PubMed PMID: 28493859; PubMed Central PMCID: PMCPMC5657988; eng.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Chapter 4: travel-related infectious diseases 2020. Yellow Book. June 24, 2019 [cited 2020 Nov 24].
   Google Scholar
• Ganesan D, Gupta SS, Legros D. Cholera surveillance and estimation of burden of cholera. Vaccine. 2020Feb29;38(Suppl 1):A13–A17. PubMed PMID: 31326254; eng.
   PubMedGoogle Scholar
• Ali M, Nelson AR, and Lopez AL, et al. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. PubMed PMID: 26043000; PubMed Central PMCID: PMCPMC4455997; eng.
   PubMed Web of Science ®Google Scholar
• WHO. Cholera, 2019. Weekly Epidemiological Rec. 2020;37:441–448.
   Google Scholar
• WHO. Ending cholera: a global roadmap to 2030. 2017.
   Google Scholar
• WHO. Current major event: arbovirus diagnostics EQAP. Weekly Epidemiological Monitor. 2019;12(50).
   Google Scholar
• Connor BA, Dawood R, and Riddle MS, et al. Cholera in travellers: a systematic review. J Travel Med. 2019Dec23;26(8):taz085. PubMed PMID: 31804684; PubMed Central PMCID: PMCPMC6927393; eng.
   PubMed Web of Science ®Google Scholar
• Mascarello M, Deiana ML, Maurel C, et al. Cholera with severe renal failure in an Italian tourist returning from Cuba, July 2013. Euro Surveill. 2013Aug29;18(35):20572. PubMed PMID: 24008229; eng.
   PubMedGoogle Scholar
• Slesak G, Fleck R, Jacob D, et al. Imported cholera with acute renal failure after a short business-trip to the Philippines, Germany, October 2015. Euro Surveill. 2016;21(1). PubMed PMID: 26767388; eng. DOI:https://doi.org/10.2807/1560-7917.es.2016.21.1.30099
   Google Scholar
• Reyes-Corcho A, Pinsker RW, Sarkar S, et al. Cholera gravis associated with acute renal failure in a traveler from Haiti to the United States. Travel Med Infect Dis. 2012Sep;10(5–6):236–239. PubMed PMID: 23137437; eng.
   PubMed Web of Science ®Google Scholar
• WHO. Advice for international travel and trade in relation to cholera. 2018.
   Google Scholar
• Harris JB. Cholera: immunity and prospects in vaccine development. J Infect Dis. 2018Oct15;218(suppl_3):S141–s146. PubMed PMID: 30184117; PubMed Central PMCID: PMCPMC6188552; eng.
   PubMedGoogle Scholar
• Leung T, Matrajt L. Immune responses to cholera following natural infection: a review. medRxiv. 2020 2020 07 27;20163139. DOI:https://doi.org/10.1101/2020.07.27.20163139
   Google Scholar
• Levine MM, Black RE, Clements ML, et al. Duration of infection-derived immunity to cholera. PubMed PMID: 7252264; eng, J Infect Dis. 1981 Jun;143(6):818–820.
   PubMed Web of Science ®Google Scholar
• Glass RI, Becker S, Huq MI, et al. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol. 1982Dec;116(6):959–970. PubMed PMID: 7148820; eng.
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, and Park JK, et al. Natural cholera infection-derived immunity in an endemic setting. J Infect Dis. 2011Sep15;204(6):912–918. PubMed PMID: 21849288; PubMed Central PMCID: PMCPMC3156915; eng.
   PubMed Web of Science ®Google Scholar
• Harris AM, Bhuiyan MS, Chowdhury F, et al. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. PubMed PMID: 19528207; PubMed Central PMCID: PMCPMC2738048. eng, Infect Immun. 2009 Sep;77(9):3850–3856.
   PubMed Web of Science ®Google Scholar
• Harris JB. Cholera: immunity and Prospects in Vaccine Development. J Infect Dis. 2018Oct15;218(suppl_3):S141–s146. PubMed PMID: 30184117; PubMed Central PMCID: PMCPMC6188552; eng.
   PubMedGoogle Scholar
• Shaikh H, Lynch J, Kim J, et al. Current and future cholera vaccines. Vaccine. 2020Feb29;38(Suppl 1):A118–a126. PubMed PMID: 31879125; eng.
   PubMedGoogle Scholar
• Islam K, Hossain M, and Kelly M, et al. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis. 2018Apr;12(4):e0006376. PubMed PMID: 29624592; PubMed Central PMCID: PMCPMC5906022; eng.
   PubMed Web of Science ®Google Scholar
• Haney DJ, Lock MD, and Simon JK, et al. Antibody-based correlates of protection against cholera: analysis of a challenge study in a cholera-naïve population. Clin Vaccine Immunol. 2017May31;24(8). PubMed PMID: 28566334; PubMed Central PMCID: PMCPMC5583470; eng. doi:https://doi.org/10.1128/cvi.00098-17
   Google Scholar
• Haney DJ, Lock MD, and Gurwith M, et al. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection. Vaccine. 2018May11;36(20):2768–2773. PubMed PMID: 29655627; PubMed Central PMCID: PMCPMC5922764; eng.
   PubMed Web of Science ®Google Scholar
• Alam MM, Riyadh MA, and Fatema K, et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol. 2011May;18(5):844–850. PubMed PMID: 21346055; PubMed Central PMCID: PMCPMC3122537; eng.
   PubMedGoogle Scholar
• Saluja T, Mogasale VV, and Excler JL, et al. An overview of Vaxchora(TM), a live attenuated oral cholera vaccine. Hum Vaccin Immunother. 2020;16(1):42–50. PubMed PMID: 31339792; PubMed Central PMCID: PMCPMC7012186; eng.
   PubMed Web of Science ®Google Scholar
• Cholera vaccines: WHO position paper. Wkly Epidemiol Rec. 2010Mar26;85(13):117–128. PubMed PMID: 20349546.
   PubMedGoogle Scholar
• WHO. Cholera vaccine stockpiles [9 June 2021 Acessed24 November 2021]. Available from: https://www.who.int/groups/icg/cholera/stockpiles
   Google Scholar
• Pezzoli L. Oral cholera vaccine working group of the global task force on cholera C. Global oral cholera vaccine use, 2013-2018. Vaccine. 2020Feb29;38(Suppl 1):A132–A140. PubMed PMID: 31519444.
   PubMedGoogle Scholar
• Bi Q, Ferreras E, and Pezzoli L, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017Oct;17(10):1080–1088. PubMed PMID: 28729167; PubMed Central PMCID: PMCPMC5639147; eng.
   PubMed Web of Science ®Google Scholar
• Deen J, Clemens JD. Licensed and recommended inactivated oral cholera vaccines: From development to innovative deployment. Trop Med Infect Dis. 2021 Mar 9. 6(1). PubMed PMID: 33803390; PubMed Central PMCID: PMCPMC8005943. DOI: https://doi.org/10.3390/tropicalmed6010032
   Google Scholar
• Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009Nov14;374(9702):1694–1702. PubMed PMID: 19819004.
   PubMed Web of Science ®Google Scholar
• Sur D, Kanungo S, Sah B, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011Oct;5(10):e1289. PubMed PMID: 22028938; PubMed Central PMCID: PMCPMC3196468.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sur D, Ali M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013Dec;13(12):1050–1056. PubMed PMID: 24140390.
   PubMed Web of Science ®Google Scholar
• Qadri F, Wierzba TF, Ali M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med. 2016May5;374(18):1723–1732. PubMed PMID: 27144848.
   PubMed Web of Science ®Google Scholar
• Qadri F, Ali M, Lynch J, et al. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. Lancet Infect Dis. 2018Jun;18(6):666–674. PubMed PMID: 29550406; eng.
   PubMed Web of Science ®Google Scholar
• Lopez AL, Deen J, and Azman AS, et al. Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and meta-analysis. Clin Infect Dis. 2018Jun1;66(12):1960–1971. PubMed PMID: 29177437; PubMed Central PMCID: PMCPMC5982790.
   PubMed Web of Science ®Google Scholar
• Mayo-Smith LM, Simon JK, and Chen WH, et al. The live attenuated cholera vaccine CVD 103-hgr primes responses to the toxin-coregulated pilus antigen TCPA in subjects challenged with wild-type vibrio cholerae. Clin Vaccine Immunol. 2017Jan;24(1):e00470–16. PubMed PMID: 27847368; PubMed Central PMCID: PMCPMC5216439; eng.
   PubMedGoogle Scholar
• Chen WH, Greenberg RN, and Pasetti MF, et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol. 2014Jan;21(1):66–73. PubMed PMID: 24173028; PubMed Central PMCID: PMCPMC3910924; eng.
   PubMed Web of Science ®Google Scholar
• Pax Vax. Vaxchora Prescribing Information. 2016 Accessed24 November 2021. Available from: https://www.fda.gov/media/98688/download
   Google Scholar
• Emergent BioSolutions. Vaxchora Summary of Product Characteristics 2020 [cited 2020 Nov 30].
   Google Scholar
• Levine MM, Chen WH, Kaper JB, et al. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines. 2017Mar;16(3):197–213. PubMed PMID: 28165831; eng.
   PubMed Web of Science ®Google Scholar
• Herzog C. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. Travel Med Infect Dis. 2016Jul-Aug;14(4):373–377. PubMed PMID: 27425792; eng.
   PubMed Web of Science ®Google Scholar
• Jaishankar J, and Srivastava P. Molecular basis of stationary phase survival and applications. Front Microbiol. 2017;8:2000. PubMed PMID: 29085349; PubMed Central PMCID: PMCPMC5650638; eng.
   PubMed Web of Science ®Google Scholar
• Migasena S, Pitisuttitham P, and Prayurahong B, et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun. 1989Nov;57(11):3261–3264. PubMed PMID: 2807523; PubMed Central PMCID: PMCPMC259791; eng.
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Levine MM, Kaper JB, et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine. 1990Dec8;(6):577–580. PubMed PMID: 2087879; eng. doi:https://doi.org/10.1016/0264-410x(90)90012-b
   Google Scholar
• Kotloff KL, Wasserman SS, and O’Donnell S, et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun. 1992Oct;60(10):4430–4432. PubMed PMID: 1398956; PubMed Central PMCID: PMCPMC257485; eng.
   PubMed Web of Science ®Google Scholar
• Suharyono SC, Simanjuntak C, and Witham, N, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992Sep19;340(8821):689–694. PubMed PMID: 1355798; eng.
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Tacket CO, and Wasserman SS, et al. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun. 1993Feb;61(2):729–733. PubMed PMID: 8423098; PubMed Central PMCID: PMCPMC302786; eng.
   PubMed Web of Science ®Google Scholar
• Wasserman SS, Kotloff KL, Losonsky GA, et al. Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect. Am J Epidemiol. 1993Dec1;138(11):988–993. PubMed PMID: 8256784; eng.
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, O’Hanley P, Punjabi NH, et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis. 1993Nov;168(5):1169–1176. PubMed PMID: 8228350; eng.
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, and Seas C, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun. 1993Sep;61(9):3994–3997. PubMed PMID: 8359923; PubMed Central PMCID: PMCPMC281106; eng.
   PubMed Web of Science ®Google Scholar
• Lagos R, Avendaño A, Horwitz I, et al. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults]. Rev Med Chil. 1993Aug; 1218: 857–863. PubMed PMID: 8296092; spa.
   PubMed Web of Science ®Google Scholar
• Wasserman SS, Losonsky GA, Noriega F, et al. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 1994Aug;12(11):1000–1003. PubMed PMID: 7975839; eng.
   PubMed Web of Science ®Google Scholar
• Lagos R, Avendaño A, and Prado V, et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun. 1995Feb;63(2):707–709. PubMed PMID: 7822046; PubMed Central PMCID: PMCPMC173056; eng.
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Que JU, and Levine MM, et al. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun. 1995Apr;63(4):1336–1339. PubMed PMID: 7890391; PubMed Central PMCID: PMCPMC173155; eng.
   PubMed Web of Science ®Google Scholar
• Kollaritsch H, Furer E, and Herzog C, et al. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect Immun. 1996Apr;64(4):1454–1457. PubMed PMID: 8606118; PubMed Central PMCID: PMCPMC173943; eng.
   PubMed Web of Science ®Google Scholar
• Lagos R, Losonsky G, Abrego P, et al. Tolerencia, immunogenicidad, excresion y transmision de la vacuna anti-cholera oral viva-atenuada, CVD 103-HgR estudio pareado de doble ciego en ninos chilenos de 24 a 59 meses. Bol Hosp Infant Mex. 1996;53:214–220.
   Google Scholar
• Kollaritsch H, Que JU, Kunz C, et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis. 1997Apr;175(4):871–875. PubMed PMID: 9086143; eng.
   PubMed Web of Science ®Google Scholar
• Pax Vax. Data on file. BB-IND 2112.
   Google Scholar
• Lagos R, Fasano A, Wasserman SS, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1999Nov;180(5):1709–1712. PubMed PMID: 10515838; eng.
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Chico ME, Losonsky G, et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis. 2000Oct;182(4):1199–1206. PubMed PMID: 10979918; eng.
   PubMed Web of Science ®Google Scholar
• McCarty JM, Lock MD, Hunt KM, et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. Vaccine. 2018Feb1;36(6):833–840. PubMed PMID: 29317118; eng.
   PubMed Web of Science ®Google Scholar
• McCarty JM, Lock MD, Bennett S, et al. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial. Vaccine. 2019Mar7;37(11):1389–1397. PubMed PMID: 30772070; eng.
   PubMed Web of Science ®Google Scholar
• Gruver AL, Hudson LL, and Sempowski GD. Immunosenescence of ageing. J Pathol. 2007Jan;211(2):144–156. PubMed PMID: 17200946; PubMed Central PMCID: PMCPMC1931833; eng.
   PubMed Web of Science ®Google Scholar
• McCarty JM, Gierman EC, and Bedell L, et al. Safety and immunogenicity of live oral cholera vaccine CVD 103-HgR in children and adolescents aged 6-17 years. Am J Trop Med Hyg. 2020Jan;102(1):48–57. PubMed PMID: 31769402; PubMed Central PMCID: PMCPMC6947768; eng.
   PubMed Web of Science ®Google Scholar
• McCarty JM, Cassie D, Bedell L, et al. Safety and immunogenicity of live oral cholera vaccine CVD 103-HgR in children aged 2-5 years in the United States. Am J Trop Med Hyg. 2021;104(3):861–865. PubMed PMID: 33319739; eng.
   Web of Science ®Google Scholar
• McCarty JM, Cassie D, and Bedell L, et al. Long term immunogenicity of live oral cholera vaccine CVD 103-HgR in adolescents 12-17 years of age in the US. Am J Trop Med Hyg. 2021 104 5 1758–1760. .
   Web of Science ®Google Scholar
• Kollaritsch H, Cryz SJ Jr., Lang AB, et al. Local and systemic immune responses to combined vibrio cholerae CVD103-HgR and salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization. Vaccine. 2000Jul1;18(26):3031–3039. PubMed PMID: 10825607; eng.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. PubMed PMID: 1527420; eng, J Infect Dis. 1992 Oct;166(4):837–841.
   PubMed Web of Science ®Google Scholar
• Chen WH, Cohen MB, and Kirkpatrick BD, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae o1 El Tor. Clin Infect Dis. 2016Jun1;62(11):1329–1335. PubMed PMID: 27001804; PubMed Central PMCID: PMCPMC4872293; eng.
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988Aug27;2(8609):467–470. PubMed PMID: 2900401; eng.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Cohen MB, and Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor Inaba three months after vaccination. Infect Immun. 1999Dec; 6712: 6341–6345. PubMed PMID: 10569747; PubMed Central PMCID: PMCPMC97039; eng.
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr., Levine MM, and Losonsky G, et al. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun. 1992Sep;60(9):3916–3917. PubMed PMID: 1500200; PubMed Central PMCID: PMCPMC257409; eng.
   PubMed Web of Science ®Google Scholar
• Su-Arehawaratana P, Singharaj P, Taylor DN, et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992Jun;165(6):1042–1048. PubMed PMID: 1583321; eng.
   PubMed Web of Science ®Google Scholar
• Lagos R, San Martin O, Wasserman SS, et al. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J. 1999Jul;18(7):624–630. PubMed PMID: 10440439; eng.
   PubMed Web of Science ®Google Scholar
• Agency EM. Summary of opinion (post authorisation) - Vaxchora cholera vaccine, oral, live 2021 [Accessed24 November 2021]. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vaxchora-ii-03-g_en.pdf
   Google Scholar
• Emergent Travel Health. Data on file. 2020.
   Google Scholar
• WHO. Cholera: key facts. 2019 Jan 17 2019 [cited 2020 Jan 17]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/cholera
   Google Scholar
• Leung AKC, Leung AAM, Wong AHC, et al. Travelers’ diarrhea: a clinical review. Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):38–48. PubMed PMID: 31084597; eng.
   PubMed Web of Science ®Google Scholar
• Wierzba TF. Oral cholera vaccines and their impact on the global burden of disease. Hum Vaccin Immunother. 2019;15(6):1294–1301. PubMed PMID: 30183486; PubMed Central PMCID: PMCPMC6663124; eng.
   PubMed Web of Science ®Google Scholar
• Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994Nov5;344(8932):1273–1276. PubMed PMID: 7967990.
   PubMed Web of Science ®Google Scholar
• Azman AS, Parker LA, Rumunu J, et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. Lancet Glob Health. 2016Nov4;(11):e856–e863. PubMed PMID: 27765293. doi:https://doi.org/10.1016/S2214-109X(16)30211-X
   Google Scholar
• Ferreras E, Chizema-Kawesha E, Blake A, et al. Single-dose cholera vaccine in response to an outbreak in Zambia. N Engl J Med. 2018Feb8;378(6):577–579. PubMed PMID: 29414267.
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet. 2005Jul2-8;366(9479):44–49. PubMed PMID: 15993232.
   PubMed Web of Science ®Google Scholar
• Khatib AM, Ali M, von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis. 2012Nov;12(11):837–844. PubMed PMID: 22954655.
   PubMed Web of Science ®Google Scholar
• Longini IM Jr., Nizam A, Ali M, et al. Controlling endemic cholera with oral vaccines. PLoS Med. 2007Nov27;4(11):e336. PubMed PMID: 18044983; PubMed Central PMCID: PMCPMC2082648.
   PubMed Web of Science ®Google Scholar
• Azman AS, Luquero FJ, Ciglenecki I, et al. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study. PLoS Med. 2015Aug;12(8):e1001867. PubMed PMID: 26305226; PubMed Central PMCID: PMCPMC4549326.
   PubMed Web of Science ®Google Scholar
• Saha A, Khan A, Salma U, et al. The oral cholera vaccine Shanchol when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine. 2016Mar18;34(13):1551–1558. PubMed PMID: 26896684.
   PubMed Web of Science ®Google Scholar
• Calain P, Chaine JP, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine. 2004Jun23;22(19):2444–2451. PubMed PMID: 15193408; eng.
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000May8;18(22):2399–2410. PubMed PMID: 10738097; eng.
   PubMed Web of Science ®Google Scholar
• Sow SO, Tapia MD, and Chen WH, et al. Randomized, placebo-controlled, double-blind phase 2 trial comparing the reactogenicity and immunogenicity of a single standard dose to those of a high dose of CVD 103-HgR live attenuated oral cholera vaccine, with shanchol inactivated oral vaccine as an open-label immunologic comparator. Clin Vaccine Immunol. 2017Dec;24(12):e00265–17. PubMed PMID: 29021299; PubMed Central PMCID: PMCPMC5717191; eng.
   PubMedGoogle Scholar
• Valcin CL, Severe K, and Riche CT, et al. Predictors of disease severity in patients admitted to a cholera treatment center in urban Haiti. Am J Trop Med Hyg. 2013Oct;89(4):625–632. PubMed PMID: 24106188; PubMed Central PMCID: PMCPMC3795091; eng.
   PubMed Web of Science ®Google Scholar
• von Seidlein L, Wang XY, Macuamule A, et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. Trop Med Int Health. 2008May;13(5):683–688. PubMed PMID: 18331384; eng.
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, and Koumaré B, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ. 1998;76(1):63–71. PubMed PMID: 9615498; PubMed Central PMCID: PMCPMC2305629; eng.
   PubMed Web of Science ®Google Scholar
• Muhsen K, Sow SO, Tapia MD, et al. Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults. Sci Rep. 2020Oct9;10(1):16871. PubMed PMID: 33037244; PubMed Central PMCID: PMCPMC7547695 Emergent Biosolutions, Gaithersburg, MD as Vaxchora. The authors declare no competing interests. eng.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wang B, et al. Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine: a systematic review and meta-analysis. Bjog. 2020Aug;127(9):1066–1073. PubMed PMID: 32289871; eng.
   PubMed Web of Science ®Google Scholar